Ads
related to: sglt2 approved for heart failure- Living With Heart Failure
Access a Heart Failure Guide.
Learn About Treatment Options.
- Heart Failure Symptoms
Access a Free Treatment Guide.
Understand Heart Failure Symptoms.
- LVAD Treatment
Free Heart Failure Treatment Guide.
Learn About LVAD Treatment Options.
- Heart Failure Stages
Access Our Heart Failure Guide.
Learn About Heart Failure Stages.
- Living With Heart Failure
Search results
Results from the WOW.Com Content Network
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...
Sotagliflozin was approved for medical use in the European Union in April 2019, as Zynquista, for the treatment for type 1 diabetes, [2] and in the United States in May 2023, [3] to reduce the risk of death due to heart failure. [1] [4] The marketing authorization for sotagliflozin was withdrawn in the EU in August 2022. [2]
Compared to a placebo, an SGLT2 by itself reduced the risk of heart attack and stroke by 11% and hospitalization for heart failure or cardiovascular death by 23%.
Dapagliflozin was approved for medical use in the United States in January 2014. [66] [36] In 2020, the US FDA expanded the indications for dapagliflozin to include treatment for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure. [11]
Merck (MRK)/Bayer's (BAYRY) vericiguat gets approval for symptomatic chronic heart failure in patients with reduced ejection fraction in Europe.
Forxiga ™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes Forxiga, a once-daily oral agent, provides ...
Ads
related to: sglt2 approved for heart failure